Bharat Parenterals Limited Q2 FY26 earnings call summary

Earnings call of 12 Nov 2025, summarised by AI from the filing.

Bharat Parenterals Q2 FY26 standalone revenue fell to ₹41.7 cr on a planned production break, but FY26 guidance of 12-14% growth and 15-17% EBITDA margin is maintained.

Key takeaways

1. US FDA EIR Innoxel received EIR from US FDA on July 30, 2025, confirming approved status for Vadodara facility.
2. Growth driver Institutional order execution shifting to H2 and export dispatches deferred to Q3; Innoxel FY27 revenue guided at ₹110-135 cr.
3. Risk Tariff pressure may push more manufacturers into ROW markets, increasing competition.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)